Mexico Transthyretin Amyloidosis (ATTR) Market Report 2022 to 2030

Mexico Transthyretin Amyloidosis (ATTR) Market Analysis

$ 3999

Mexico Transthyretin Amyloidosis (ATTR) Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Transthyretin Amyloidosis (ATTR) market is growing globally due to the increase in disease awareness, advancements in diagnostic techniques, development of disease-modifying therapies, growing investment in research and development, regulatory support and expedited approvals, collaboration and partnerships between pharmaceutical companies and academic institutions. Pfizer Inc, AstraZeneca, Prothena Corporation plc, Ionis Pharmaceuticals, BELLUS Health Inc , Alnylam Pharmaceuticals, Inc, Eidos Therapeutics, Inc, SOM BIOTECH, Abbvie, Inc., Bausch Health Companies Inc., Bristol Myers Squibb Company, GSK Plc. are the key global market players in transthyretin amyloidosis (ATTR) market.

ID: IN10MXPH411 CATEGORY: Pharmaceuticals GEOGRAPHY: Middle East AUTHOR: Dr. Medha Sansanwal

Buy Now

Mexico Transthyretin Amyloidosis (ATTR) Market Analysis Summary

Mexico Transthyretin Amyloidosis (ATTR) Market is valued at around $75.8 Mn in 2022 and is projected to reach $145.4 Mn by 2030, exhibiting a CAGR of 8.5% during the forecast period 2023-2030.

Transthyretin amyloidosis (ATTR) is a rare disease characterized by the deposition of abnormal transthyretin protein as amyloid fibrils in various organs. Two primary forms of ATTR are hereditary (hATTR) and wild-type (ATTRwt). Transthyretin, which is made by the liver and forms dimers before becoming monomers, causes transthyretin amyloidosis. The symptoms of familial amyloid polyneuropathy usually appear when the patient becomes 30, though they can also appear in the early 20s or the late 80s. When cardiac biomarkers like troponin and the N-terminal segment of brain natriuretic peptide are found in unusually high amounts in the heart, they cause amyloid deposits that can aid in further illness identification. If too much amyloid protein begins to build up in the nerves, symptoms could get worse. Cardiac symptoms like arrhythmias, cardiomyopathy, neuropathy symptoms like peripheral neuropathy, and renal dysfunction occur.

Market Dynamics

Market Growth Drivers

Increase in disease awareness, advancements in diagnostic techniques, development of disease-modifying therapies, growing investment in research and development, regulatory support and expedited approvals, collaboration, and partnerships between pharmaceutical companies and academic institutions act as market growth drivers.

Market Restraints

Complex diagnostic processes, high treatment costs, limited treatment options, disease progression and organ damage, clinical trial challenges, and regulatory and reimbursement issues act as market growth restraints.

Competitive Landscape

Key Player

Pfizer Inc
AstraZeneca
Prothena Corporation plc
Ionis Pharmaceuticals
BELLUS Health Inc
Alnylam Pharmaceuticals, Inc
Eidos Therapeutics, Inc
SOM BIOTECH
Abbvie, Inc.
Bausch Health Companies Inc.
Bristol Myers Squibb Company
GSK Plc.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Mexico Transthyretin Amyloidosis (ATTR) Market

By Drug Type

Tafamidis
Patisiran
Inotersen
Others

By Disease Type

Hereditary Transthyretin Amyloidosis

By End-Users

Hospitals
Homecare
Specialty Clinics
Others

By Distribution Channel

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.